On Thursday, Shares of Pfizer Inc. (NYSE:PFE), gained 1.23% to $33.86.
Pfizer Inc., declared enrollment of the first patient in a Phase 2b clinical trial of its investigational Staphylococcus aureus (S. aureus) multi-antigen vaccine (PF-06290510) in adults undergoing elective spinal fusion surgery. The purpose of the study, named STRIVE (STaphylococcus aureus SuRgical Inpatient Vaccine Efficacy), is to evaluate the safety and efficacy of the vaccine to determine if it prevents postoperative invasive S. aureus infections in patients undergoing elective spinal surgery.
Surgical Site Infections (SSIs) are a noteworthy and growing concern. SSIs caused by S. aureus account for about 20 percent of all SSIs in the U.S., and are associated with an estimated annual treatment cost of $12.3 billion in the U.S. Patients who suffer such infections due to antibiotic resistant (MRSA) or antibiotic sensitive (MSSA) S.aureus have worse clinical outcomes, counting raised mortality in comparison with non-infected patients.
Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. The company operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments.
Shares of T-Mobile US, Inc. (NYSE:TMUS), inclined 0.78% to $38.77, during its last trading session.
T-Mobile US, has unveiled the latest in its Un-carrier Amped declarements—and this one’s going to make history. The company recently declared a massive expansion of its first industry-rocking Un-carrier™ move, Simple Choice™, extending coverage and calling across the U.S., Mexico & Canada for all Simple Choice customers at no extra charge. Called ‘Mobile without Borders,’ this first-of-its-kind move delivers calling to both land lines and mobile phones − in addition to 4G LTE data straight from your plan − across all three countries at no additional cost. The epic upgrade makes Simple Choice the first and only wireless plan to span an entire continent.
The move eliminates a major pain point for U.S. wireless customers. Last year, a full 35% of all international calls and 55% of all international travel from the U.S. was to Mexico & Canada alone. Over 70% of international trips taken by small and mid-sized business travelers were to Mexico & Canada. And, the same year, the carriers raked in nearly $10 billion in global roaming charges at over 90% margins. Meaning the carriers are lining their pockets with billions of dollars in inflated roaming fees—for coverage the Un-carrier now comprises at no extra cost.
T-Mobile US, Inc., together with its auxiliaries, provides mobile communications services in the United States, Puerto Rico, and the U.S. Virgin Islands. The company offers voice, messaging, and data services in the postpaid, prepaid, and wholesale markets.
Finally, Celldex Therapeutics, Inc. (NASDAQ:CLDX), ended its last trade with 0.78% gain, and closed at $24.47.
Celldex Therapeutics, declared the promotion of Richard Wright, Ph.D. to Senior Vice President and the newly created position of Chief Commercial Officer. Dr. Wright was formerly Vice President of Commercial Operations at Celldex and brings nearly 25 years of industry experience, counting the commercialization of six successful drug therapies. As Chief Commercial Officer, Dr. Wright is responsible for developing global business strategy and building the infrastructure required to support commercialization of Celldex’s cancer immunotherapy pipeline.
Celldex Therapeutics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes novel therapeutics for human health care in the United States. The company’s lead drug candidates comprise rindopepimut (CDX-110), a targeted immunotherapeutic in a pivotal Phase III study for the treatment of front-line glioblastoma, in addition to in Phase II study for the treatment of recurrent glioblastoma.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
